Cargando…

Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions

Lung cancer still represents a global health problem, being the main type of tumor responsible for cancer deaths. In this context, the tumor microenvironment, and the extracellular matrix (ECM) pose as extremely relevant. Thus, this study aimed to explore the prognostic value of epithelial-to-mesenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldavira, Camila Machado, Prieto, Tabatha Gutierrez, Machado-Rugolo, Juliana, de Miranda, Jurandir Tomaz, de Oliveira, Lizandre Keren Ramos, Velosa, Ana Paula Pereira, Teodoro, Walcy Rosolia, Ab’Saber, Alexandre, Takagaki, Teresa, Capelozzi, Vera Luiza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703002/
https://www.ncbi.nlm.nih.gov/pubmed/36452484
http://dx.doi.org/10.3389/fonc.2022.1042766
_version_ 1784839768874418176
author Baldavira, Camila Machado
Prieto, Tabatha Gutierrez
Machado-Rugolo, Juliana
de Miranda, Jurandir Tomaz
de Oliveira, Lizandre Keren Ramos
Velosa, Ana Paula Pereira
Teodoro, Walcy Rosolia
Ab’Saber, Alexandre
Takagaki, Teresa
Capelozzi, Vera Luiza
author_facet Baldavira, Camila Machado
Prieto, Tabatha Gutierrez
Machado-Rugolo, Juliana
de Miranda, Jurandir Tomaz
de Oliveira, Lizandre Keren Ramos
Velosa, Ana Paula Pereira
Teodoro, Walcy Rosolia
Ab’Saber, Alexandre
Takagaki, Teresa
Capelozzi, Vera Luiza
author_sort Baldavira, Camila Machado
collection PubMed
description Lung cancer still represents a global health problem, being the main type of tumor responsible for cancer deaths. In this context, the tumor microenvironment, and the extracellular matrix (ECM) pose as extremely relevant. Thus, this study aimed to explore the prognostic value of epithelial-to-mesenchymal transition (EMT), Wnt signaling, and ECM proteins expression in patients with non–small-cell lung carcinoma (NSCLC) with clinical stages I-IIIA. For that, we used 120 tissue sections from patients and evaluated the immunohistochemical, immunofluorescence, and transmission electron microscopy (TEM) to each of these markers. We also used in silico analysis to validate our data. We found a strong expression of E-cadherin and β-catenin, which reflects the differential ECM invasion process. Therefore, we also noticed a strong expression of chondroitin sulfate (CS) and collagens III and V. This suggests that, after EMT, the basal membrane (BM) enhanced the motility of invasive cells. EMT proteins were directly associated with WNT5A, and collagens III and V, which suggests that the WNT pathway drives them. On the other hand, heparan sulfate (HS) was associated with WNT3A and SPARC, while WNT1 was associated with CS. Interestingly, the association between WNT1 and Col IV suggested negative feedback of WNT1 along the BM. In our cohort, WNT3A, WNT5A, heparan sulfate and SPARC played an important role in the Cox regression model, influencing the overall survival (OS) of patients, be it directly or indirectly, with the SPARC expression stratifying the OS into two groups: 97 months for high expression; and 65 for low expression. In conclusion, the present study identified a set of proteins that may play a significant role in predicting the prognosis of NSCLC patients with clinical stages I-IIIA.
format Online
Article
Text
id pubmed-9703002
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97030022022-11-29 Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions Baldavira, Camila Machado Prieto, Tabatha Gutierrez Machado-Rugolo, Juliana de Miranda, Jurandir Tomaz de Oliveira, Lizandre Keren Ramos Velosa, Ana Paula Pereira Teodoro, Walcy Rosolia Ab’Saber, Alexandre Takagaki, Teresa Capelozzi, Vera Luiza Front Oncol Oncology Lung cancer still represents a global health problem, being the main type of tumor responsible for cancer deaths. In this context, the tumor microenvironment, and the extracellular matrix (ECM) pose as extremely relevant. Thus, this study aimed to explore the prognostic value of epithelial-to-mesenchymal transition (EMT), Wnt signaling, and ECM proteins expression in patients with non–small-cell lung carcinoma (NSCLC) with clinical stages I-IIIA. For that, we used 120 tissue sections from patients and evaluated the immunohistochemical, immunofluorescence, and transmission electron microscopy (TEM) to each of these markers. We also used in silico analysis to validate our data. We found a strong expression of E-cadherin and β-catenin, which reflects the differential ECM invasion process. Therefore, we also noticed a strong expression of chondroitin sulfate (CS) and collagens III and V. This suggests that, after EMT, the basal membrane (BM) enhanced the motility of invasive cells. EMT proteins were directly associated with WNT5A, and collagens III and V, which suggests that the WNT pathway drives them. On the other hand, heparan sulfate (HS) was associated with WNT3A and SPARC, while WNT1 was associated with CS. Interestingly, the association between WNT1 and Col IV suggested negative feedback of WNT1 along the BM. In our cohort, WNT3A, WNT5A, heparan sulfate and SPARC played an important role in the Cox regression model, influencing the overall survival (OS) of patients, be it directly or indirectly, with the SPARC expression stratifying the OS into two groups: 97 months for high expression; and 65 for low expression. In conclusion, the present study identified a set of proteins that may play a significant role in predicting the prognosis of NSCLC patients with clinical stages I-IIIA. Frontiers Media S.A. 2022-11-14 /pmc/articles/PMC9703002/ /pubmed/36452484 http://dx.doi.org/10.3389/fonc.2022.1042766 Text en Copyright © 2022 Baldavira, Prieto, Machado-Rugolo, de Miranda, de Oliveira, Velosa, Teodoro, Ab’Saber, Takagaki and Capelozzi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Baldavira, Camila Machado
Prieto, Tabatha Gutierrez
Machado-Rugolo, Juliana
de Miranda, Jurandir Tomaz
de Oliveira, Lizandre Keren Ramos
Velosa, Ana Paula Pereira
Teodoro, Walcy Rosolia
Ab’Saber, Alexandre
Takagaki, Teresa
Capelozzi, Vera Luiza
Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions
title Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions
title_full Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions
title_fullStr Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions
title_full_unstemmed Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions
title_short Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions
title_sort modeling extracellular matrix through histo-molecular gradient in nsclc for clinical decisions
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703002/
https://www.ncbi.nlm.nih.gov/pubmed/36452484
http://dx.doi.org/10.3389/fonc.2022.1042766
work_keys_str_mv AT baldaviracamilamachado modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions
AT prietotabathagutierrez modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions
AT machadorugolojuliana modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions
AT demirandajurandirtomaz modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions
AT deoliveiralizandrekerenramos modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions
AT velosaanapaulapereira modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions
AT teodorowalcyrosolia modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions
AT absaberalexandre modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions
AT takagakiteresa modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions
AT capelozziveraluiza modelingextracellularmatrixthroughhistomoleculargradientinnsclcforclinicaldecisions